Rex Medical, L.P.


in

Angiotech Pharmaceuticals Inc. has entered into a definitive licensing agreement with privately held Rex Medical, L.P. for exclusive worldwide rights to market and distribute the Option(TM) inferior vena cava (IVC) filter, a medical device that is implanted into the body's inferior vena cava to prevent pulmonary embolism (PE). Angiotech and Rex Medical will be exhibiting at the 33rd Annual Meeting of the Society of Interventional Radiology (SIR) to be held in Washington, DC from March 15-18, 2008. Financial terms of the agreement were not disclosed.